The Food and Drug Administration on Friday authorized Eli Lilly's monoclonal antibody treatment for infants and children under age 12 with Covid-19 who are at high risk of becoming severely ill from the virus because they have a condition such as obesity or diabetes.
[
add
]
[
|
|
...
]